Analyst Rating Update on Myriad Genetics (MYGN)

Myriad Genetics (NASDAQ:MYGN) has an average broker rating of 2.38, which is interpreted as a Buy, as rated by 14 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 2 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Myriad Genetics (NASDAQ:MYGN) : Average target price received by Myriad Genetics (NASDAQ:MYGN) is $39.67 with an expected standard deviation of $7.87. The most aggressive target on the stock is $50, whereas the most downbeat target is $25. 9 financial analysts are currently covering the stock.

Company shares have received an average consensus rating of Hold for the current week Also, Avondale Partners maintains its view on Myriad Genetics (NASDAQ:MYGN) according to the research report released by the firm to its investors. The shares have now been rated Market Outperform by the stock experts at the ratings house. Avondale Partners lowers the price target from $50 per share to $47 per share on Myriad Genetics . The rating by the firm was issued on May 4, 2016.

Myriad Genetics (NASDAQ:MYGN): stock turned positive on Tuesday. Though the stock opened at $29.47, the bulls momentum made the stock top out at $30.01 level for the day. The stock recorded a low of $29.37 and closed the trading day at $29.58, in the green by 1.58%. The total traded volume for the day was 917,174. The stock had closed at $29.12 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (President, MGL) of Myriad Genetics Inc, Ford Alexander had sold 18,637 shares worth of $575,324 in a transaction dated June 21, 2016. In this transaction, 18,637 shares were sold at $30.87 per share.

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.